REGENXBIO (RGNX) Competitors

REGENXBIO (NASDAQ:RGNX) and Belite Bio (NASDAQ:BLTE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Is RGNX or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to REGENXBIO's net margin of -283.19%. Belite Bio's return on equity of -31.94% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-283.19%	-70.65%	-41.68%
Belite Bio	N/A	-31.94%	-30.73%

Which has more risk and volatility, RGNX or BLTE?

REGENXBIO has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.44, suggesting that its share price is 244% less volatile than the S&P 500.

Do institutionals and insiders believe in RGNX or BLTE?

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 12.8% of REGENXBIO shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the MarketBeat Community believe in RGNX or BLTE?

REGENXBIO received 408 more outperform votes than Belite Bio when rated by MarketBeat users. However, 94.74% of users gave Belite Bio an outperform vote while only 65.49% of users gave REGENXBIO an outperform vote.

Company	Underperform	Outperform
REGENXBIO	Outperform Votes 444 65.49%	Underperform Votes 234 34.51%
Belite Bio	Outperform Votes 36 94.74%	Underperform Votes 2 5.26%

Which has higher valuation and earnings, RGNX or BLTE?

Belite Bio has lower revenue, but higher earnings than REGENXBIO. Belite Bio is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$156.72M	3.26	-$263.49M	-$3.11	-3.28
Belite Bio	N/A	N/A	-$31.63M	-$1.36	-45.15

Does the media refer more to RGNX or BLTE?

In the previous week, REGENXBIO had 1 more articles in the media than Belite Bio. MarketBeat recorded 11 mentions for REGENXBIO and 10 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.69 beat REGENXBIO's score of 0.49 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Belite Bio	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate RGNX or BLTE?

REGENXBIO currently has a consensus target price of $31.63, suggesting a potential upside of 210.05%. Belite Bio has a consensus target price of $96.67, suggesting a potential upside of 57.44%. Given REGENXBIO's higher probable upside, equities analysts plainly believe REGENXBIO is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Belite Bio	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Belite Bio beats REGENXBIO on 9 of the 17 factors compared between the two stocks.